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Pyronaridine, a Mannich base antimalarial, has demonstrated high in vivo and in vitro efficacy against
chloroquine-resistant Plasmodium falciparum. Although this drug has the potential to become a prominent
artemisinin combination therapy, little is known about its efficacy against drug-resistant Plasmodium vivax. The
in vitro antimalarial susceptibility of pyronaridine was assessed in multidrug-resistant P. vivax (n  99) and
P. falciparum (n  90) isolates from Papua, Indonesia, using a schizont maturation assay. The median 50%
inhibitory concentration (IC50) of pyronaridine was 1.92 nM (range, 0.24 to 13.8 nM) against P. falciparum and
2.58 nM (range, 0.13 to 43.6 nM) against P. vivax, with in vitro susceptibility correlating significantly with
chloroquine, amodiaquine, and piperaquine (rs [Spearman’s rank correlation coefficient]  0.45 to 0.62; P <
0.001). P. falciparum parasites initially at trophozoite stage had higher IC50s of pyronaridine than those
exposed at the ring stage (8.9 nM [range, 0.6 to 8.9 nM] versus 1.6 nM [range, 0.6 to 8.9 nM], respectively; P
0.015), although this did not reach significance for P. vivax (4.7 nM [range, 1.4 to 18.7 nM] versus 2.5 nM
[range, 1.4 to 15.6 nM], respectively; P  0.085). The excellent in vitro efficacy of pyronaridine against both
chloroquine-resistant P. vivax and P. falciparum highlights the suitability of the drug as a novel partner for
artemisinin-based combination therapy in regions where the two species are coendemic.
Almost 40% of the world’s population is at risk for infection
by Plasmodium vivax, with an estimated 132 to 391 million
clinical infections each year (19). Although chloroquine (CQ)
remains the treatment of choice in most of the P. vivax-en-
demic world, this status is now being undermined by the emer-
gence and spread of chloroquine-resistant (CQR) P. vivax.
First reported in the 1980s on the island of New Guinea (2, 23),
CQR P. vivax has since spread to other parts of Asia and
recently to South America (1). In Papua, Indonesia, CQ resis-
tance in P. vivax has reached levels precluding the use of CQ in
most of the province (22, 30). There is an urgency to assess the
efficacies of alternative antimalarial agents against drug-resis-
tant P. vivax and to develop new strategies to combat the
parasite.
Pyronaridine (Pyr), a Mannich base synthesized in China in
the 1970s (3, 16), is being developed as a novel antimalarial for
multidrug-resistant malaria. It demonstrates potent in vitro
activity against erythrocytic stages of Plasmodium falciparum
(8, 24, 26, 36), retaining efficacy against CQR isolates (12, 17,
18). Clinical trials have shown excellent efficacy of mono-
therapy against multidrug-resistant falciparum malaria (14, 24,
25), with the early therapeutic response faster when combined
with artesunate (20). Phase III studies with a coformulation of
Pyramax (Shin Poong Pharmaceuticals) containing artesunate
plus pyronaridine have recently been completed (34).
Less is known of the antimalarial properties of pyronaridine
against P. vivax, although early clinical studies in China dem-
onstrated a rapid therapeutic response (3). To investigate the
activity of pyronaridine against CQR P. vivax, we applied a
modified schizont maturation assay on fresh field isolates from
Papua, Indonesia, where CQR P. vivax is highly prevalent.
MATERIALS AND METHODS
Field location and sample collection. Plasmodium sp. isolates were collected
from patients with uncomplicated malaria presenting to the Rumah Sakit Mitra
Masyarakat (RSMM) hospital between January 2006 and July 2007. RSMM is
situated on the southern coast of Papua, Indonesia, in a forested lowland area
where malaria transmission is unstable, with an estimated annual incidence of
802 per 1,000 person years (divided 57:43 between P. falciparum and P. vivax
infections) (11). Drug-resistant strains of P. vivax and P. falciparum are endemic
to the area, with the risk of treatment failure reaching 65% within 28 days after
chloroquine monotherapy for vivax malaria and 48% after chloroquine plus
sulfadoxine-pyrimethamine (SP) for falciparum malaria (22). Patients with symp-
tomatic malaria presenting to an outpatient facility were recruited into the study
if singly infected with P. falciparum or P. vivax with a parasitemia between 2,000
l1 and 80,000 l1. These criteria reflect the technical difficulties of reliably
quantifying parasite stages using microscopy at low parasitemias. Although they
may raise potential attrition bias, the criteria include the majority of patients
presenting with clinical malaria in this region (geometric mean parasitemia,
1,600 to 3,000 l1) (9, 21). Patients treated with antimalarials in the previous 3
weeks were excluded from the study. Venous blood (5 ml) was collected by
venipuncture, host white blood cells were removed using a CF11 column, and
packed infected red blood cells (IRBC) were used for the in vitro drug suscep-
tibility assay.
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In vitro drug susceptibility assay. The antimalarial susceptibilities of P. vivax
and P. falciparum isolates were measured using a protocol modified from the
WHO microtest as described previously (27, 28). In this test, drug activity is
presented as inhibition of parasite growth from ring stage to schizont but does
not quantify any activity on merozoites or reinvasion. Two hundred microliters of
a 2% hematocrit blood medium mixture (BMM), consisting of RPMI 1640
medium plus 10% AB human serum (P. falciparum) or McCoy’s 5A medium
plus 20% AB human serum (P. vivax), was added to each well of predosed drug
plates. Each drug plate contained 11 serial concentrations (2-fold dilutions) of
the antimalarials, with maximum concentrations of 87 nM for pyronaridine, 5,910
nM for chloroquine, 557 nM for amodiaquine, 93 nM for artesunate, 338 nM for
mefloquine, and 769 nM for piperaquine. The parasites were cultured to mature
them in a candle jar at 37.5°C for 21 to 46 h. Incubation was stopped and the
plates were harvested when40% of ring stage parasites had reached the mature
schizont stage in the drug-free control.
Thick blood films made from each well were stained with 5% Giemsa solution
for 30 min and examined microscopically. Differential counts of 200 asexual
parasites in both the preincubation and test slides were classified into ring stage
(ring-shaped trophozoites without pigment), mature trophozoites (a single chro-
matin dot and hemazoin pigment visible), and schizonts (two or more chromatin
dots).
To determine the effect of the antimalarial, the number of schizonts (5
chromatin dots visible per 200 asexual-stage parasites, with the stricter definition
for the count improving assay accuracy) was determined for each drug concen-
tration and normalized to the control well. Free merozoites and gametocytes
were not included in the count. The dose-response data were analyzed using
nonlinear regression analysis (WinNonLin 4.1; Pharsight Corporation), and the
50% inhibitory concentration (IC50) was derived using an inhibitory sigmoid
Emax model. Only IC50 in vitro data from predicted curves where the Emax
(maximum effect) and E0 (minimum effect) were within 15% of 100 or 0, re-
spectively, were used.
Data analysis. Analysis was performed using SPSS for Windows (v. 15; SPSS
Inc., Chicago, IL). The Mann-Whitney U test or the Kruskal-Wallis method was
used for nonparametric comparisons. For categorical variables, percentages and
corresponding 95% confidence intervals (CI) were calculated using Wilson’s
method. Proportions were examined using 2 with Yates’ correction or by Fish-
er’s exact test. The level of statistical significance was taken as a P value of0.05,
with Bonferroni correction for multiple comparisons.
Previous studies have highlighted the importance of the initial stage of the
parasite and the duration of the assay for derived IC50s. Therefore, the results for
P. vivax were presented in a post hoc selection of isolates with a majority of ring
stage parasites at enrollment and an assay duration between 30 and 50 h (27).
Ethical approval. Ethical approval for this study was obtained from the ethics
committees of the National Institute of Health Research and Development,
Ministry of Health, Indonesia, and the Menzies School of Health Research,
Darwin, Australia.
RESULTS
Between January 2006 and July 2007, the in vitro suscepti-
bility of pyronaridine was assessed in 221 patients with single-
species infections by either P. vivax (n  117) or P. falciparum
(n 104). Susceptibility profiles for the same isolates were also
tested against chloroquine, amodiaquine, artesunate, meflo-
quine, and piperaquine. The baseline characteristics of these
isolates are presented in Table 1. Adequate growth for harvest
was achieved in 87% (90/104) of P. falciparum isolates and
85% (99/117) of P. vivax isolates, with a mean schizont count at
harvest of 53% (95% CI, 50 to 56).
Initial stage of the parasite and in vitro susceptibility. There
was a significant difference between the synchronicities of P.
falciparum and P. vivax isolates. Whereas the median propor-
tion of ring stages in the P. falciparum isolates was 100%
(range, 93 to 100%), this proportion fell to 49% (range, 0 to
99%) in P. vivax isolates (P  0.0001), with only 50% (50/99)
of the isolates successfully processed having a ring-to-tropho-
zoite ratio (RT ratio) greater than 1. The RT ratio for P. vivax
at the start of culture was correlated significantly with the IC50s
for chloroquine (rs  0.460; P  0.001) and mefloquine (rs 
0.295; P 0.015), but this was not apparent for pyronaridine,
piperaquine, amodiaquine, or artesunate.
To investigate the stage-specific drug susceptibility in Plas-
modium, isolates with greater than 90% rings were set up in
culture in the presence of drug directly and again after culture
in the absence of drug to achieve 90% trophozoites. Isolates
assayed at ring stage had significantly lower IC50s of pyronari-
dine than the same isolates assayed at trophozoite stage for P.
TABLE 2. In vitro susceptibilities for paired isolates tested at ring (90% before culture) and trophozoite (90% after culture in the
absence of drug) stages
Drug
P. falciparum P. vivax
n
Median IC50 (range) (nM)
P n
Median IC50 (range) (nM)
P
Rings Trophozoites Rings Trophozoites
Pyronaridine 11 1.6 (0.6–8.9) 8.0 (1.2–21.7) 0.015 8 2.5 (1.4–15.6) 4.7 (1.4–18.7) 0.085
Chloroquine 8 34.6 (11.9–55.0) 60.6 (19.6–157.8) 0.125 8 49.2 (18.3–171.8) 2427 (384–4457) 0.04
Amodiaquine 8 8.1 (2.6–16.2) 12.6 (0.4–22.4) 0.805 8 16.5 (6.7–37.9) 25.2 (12.5–59.9) 0.18
Mefloquine 11 4.9 (1.6–14.8) 8.5 (2.4–34.1) 0.04 8 7.9 (1.3–24.6) 12.4 (1.9–25.0) 0.615
Piperaquine 10 11.8 (2.7–30.4) 77.2 (13.6–1195) 0.025 8 14.0 (8.4–42.0) 21.7 (10.5–62.0) 0.085
TABLE 1. Characteristics of isolates for which an in vitro assay was accomplished
Baseline characteristic
Value
P. falciparum P. vivax
Total no. assayed 90 99
Median (range) delay from venipuncture to start of culture (h) 1.7 (0.8–4.6) 1.7 (0.3–4.6)
Median (range) duration of assay (h) 31 (24–53) 29 (24–56)
Geometric mean (95% CI), parasitemia (no. of asexual parasites/l) 14,197 (12,093–16,667) 8,364 (7,184–9,741)
Median initial % (range) of parasites at ring stage 100 (93–100) 49 (0–99)
Mean (95% CI) % schizonts at harvest 61.9 (58.1–65.6) 44.8 (41.2–47.6)
VOL. 54, 2010 PYRONARIDINE ACTIVITY AGAINST P. FALCIPARUM AND P. VIVAX 5147
 o
n
 Septem
ber 3, 2013 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
falciparum (median, 1.6 nM [range, 0.6 to 8.9 nM] versus 8.0
nM [range, 1.2 to 21.7 nM]; P  0.015), but not P. vivax. The
derived IC50s of P. falciparum were also significantly lower for
mefloquine and piperaquine, whereas in P. vivax, differential
drug activity was apparent only for chloroquine (Table 2).
Duration of the assay and in vitro susceptibility. The median
time to reach the threshold for harvest was 31 h (range, 24 to
53 h) for P. falciparum and 29 h (range, 24 to 56 h) for P. vivax
(P  0.505). In P. vivax, the duration of the assay was highly
correlated with the RT ratio prior to culture (rs  0.645; P 
0.001), but this was not apparent for P. falciparum isolates,
which were predominantly at the ring stage prior to culture. A
negative correlation between the duration of the assay and P.
vivax IC50s was observed for chloroquine (rs  0.629; P 
0.001) (Fig. 1a), pyronaridine (rs0.260; P 0.05) (Fig. 1b),
amodiaquine (rs  0.317; P  0.01), mefloquine (rs 
0.490; P  0.001), and piperaquine (rs  0.432; P  0.001),
but not artesunate (rs  0.000; P  0.995). After the revised
selection criteria were applied, 36 P. vivax isolates initially at
majority ring stage (50% rings) had assay durations between
30 and 50 h. In this reduced sample set, there was no significant
correlation between the duration of the assay and the IC50 for
any drug tested.
Antimalarial susceptibility. The overall median IC50s are
presented in Table 3. The IC50s of pyronaridine for both, P.
falciparum and P. vivax were significantly lower than those for
all of the other drugs (P  0.001), with the exception of arte-
sunate, which had the lowest IC50 of any drug tested (P 
0.001). The pyronaridine susceptibility was positively corre-
lated with chloroquine, amodiaquine, and piperaquine in both
P. falciparum (rs 0.449 to 0.746; P 0.001) and P. vivax (rs
0.523 to 0.721; P  0.001) assays (Table 4). Whereas arte-
sunate susceptibility in P. falciparum was correlated with
pyronaridine (rs  0.636; P  0.001) and mefloquine (rs 
0.286; P  0.035), this was not apparent in P. vivax.
DISCUSSION
In Southeast Asia and South America, P. vivax accounts for
up to 50 to 70% of symptomatic malaria. Whereas the World
Health Organization advocates the use of artemisinin combi-
nation therapies (ACTs) for P. falciparum, chloroquine re-
mains the mainstay of treatment for P. vivax, with the inevita-
ble consequence that in areas where both species are endemic
a dual treatment policy is often necessary. Such an approach is
being increasingly undermined by the emergence and spread of
chloroquine-resistant P. vivax. Several countries where drug
resistance is present in both species have chosen to implement
a unified antimalarial policy (7). However, since the molecular
mechanisms of drug resistance in P. vivax are clearly different
from those in P. falciparum (15, 32), one cannot assume that
the susceptibility of one species to a particular treatment reg-
imen implies susceptibility in the other.
In vitro drug susceptibility testing is used routinely to mon-
itor antimalarial drug resistance in P. falciparum and to screen
for novel antimalarial compounds. Similar approaches in P.
vivax are much more difficult, since unlike P. falciparum, this
parasite preferentially invades young red blood cells, reducing
FIG. 1. Scatter plots of the duration of the assay with the derived in
vitro susceptibility (IC50) for chloroquine (a) and pyronaridine (b).
Open circles, isolates initially predominantly at trophozoite stage;
closed circles, isolates initially predominantly at ring stage.
TABLE 3. Overall in vitro sensitivity for each drug according to the species tested
Drug
P. falciparum
P. vivax
All 50% rings and assay duration30–50 h
n Median IC50(range) (nM) n
Median IC50 (range)
(nM) n
Median IC50
(range) (nM)
Pyronaridine 90 1.92 (0.24–13.8) 98 2.58 (0.13–43.6) 36 2.4 (0.13–17.2)
Chloroquine 90 43.6 (7.3–120.3) 90 141.5 (4.6–3506) 36 55.3 (4.6–1411)
Amodiaquine 89 5.7 (1.4–25.8) 97 14.0 (0.37–95.8) 37 12.0 (0.37–42.2)
Artesunate 71 0.68 (0.06–5.05) 91 1.03 (0.04–13.6) 30 1.27 (0.08–12.0)
Mefloquine 88 4.9 (0.32–28.8) 98 12.1 (0.81–175.6) 36 8.0 (0.81–29.8)
Piperaquine 89 17.1 (1.5–107.2) 97 24.8 (1.8–160.6) 36 19.6 (1.8–74.6)
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parasite growth and confounding continuous ex vivo culture (8,
35). To overcome this, short-term assays with field isolates of
asexual parasites fresh from the human host have been used to
evaluate the inhibitory effects of antimalarials on P. vivax (6,
28, 33). Our previous studies have demonstrated that isolates
of P. vivax initially at the trophozoite stage are intrinsically
resistant to chloroquine (27, 29), and indeed, the results of the
current study confirm these findings. Since the synchronicity of
infection varies between geographical locations and with the
age of the patient, it is critical that the in vitro drug response be
interpreted according to the initial stage of the parasite and the
duration of the assay. The current in vitro susceptibility assay
has shown utility in confirming the presence of emerging drug
resistance (5, 10, 32), characterizing drug susceptibility profiles
(5, 31), and screening for susceptibility to therapeutic agents
(13). More recently, we have revised the assay criteria so that
the quantification of parasite growth is restricted to parasites
that have been exposed to the drug through all stages of the
asexual life cycle (27). These more stringent criteria demand
that the initial isolates be predominantly at the ring stage and
be cultured for between 30 and 50 h. Under such conditions,
any parasites initially at trophozoite stage will have matured to
schizonts and ruptured and thus will not be quantified using
microscopy-based quantification methods.
In the present study, we applied our modified schizont mat-
uration test to assess the in vitro antimalarial activity of py-
ronaridine, an important new schizontocidal drug. Previous
studies have documented the in vitro activity of pyronaridine in
P. falciparum, highlighting high efficacies against both chloro-
quine-sensitive and -resistant strains (4, 12, 18, 26). Our study
confirms similarly high activity against multidrug-resistant P.
falciparum from southern Papua and also demonstrates its
potency against highly drug-resistant strains of P. vivax, with
IC50s in the low nanomolar range. Compared to the other
drugs tested, only artesunate showed greater antiparasitic ac-
tivity.
In keeping with our previous studies, we found that antima-
larial in vitro activity varied with the initial stage of the parasite,
with trophozoites reaching the threshold for harvest more
quickly and having higher derived IC50s. This was particularly
apparent for chloroquine in P. vivax but was also apparent,
albeit to a lesser degree, in the activities of pyronaridine, pi-
peraquine, and mefloquine. Analysis of P. vivax susceptibility
was therefore restricted to the 37% of isolates initially pre-
dominantly at ring stage prior to culture, with assay durations
of 30 to 50 h. There was significant correlation between py-
ronaridine IC50s and the other drugs. Although this could
suggest cross-resistance, only 26% of variation in activity could
be explained by variation in chloroquine activity, with pyronari-
dine retaining extremely high activity against all isolates; the
derived IC50 never exceeded 17.2 nM. The correlation coeffi-
cients were significantly higher between pyronaridine and amo-
diaquine (another quinoline-type Mannich base) and pipera-
quine (a bis-4-amino-quinoline), with variation in the activities
of these compounds explaining 54% and 37% variation of
pyronaridine, respectively.
Laboratory-adapted strains of P. vivax that can be used for
screening novel antimalarial agents against P. vivax have yet to
be developed. Our modified schizont maturation assay, carried
out under field conditions in southern Papua, suggests that
pyronaridine retains excellent susceptibility against multidrug-
resistant strains of both P. falciparum and P. vivax. These
results are reassuring as the novel artesunate-pyronaridine
combination continues to be tracked in different endemic set-
tings.
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